Equities research analysts at Zacks Investment Research upgraded shares of Orthofix International (NASDAQ: OFIX) from a “neutral” rating to an “outperform” rating in a research note to clients and investorson Friday.
Orthofix International N.V. (Orthofix) is a diversified orthopedic products company offering a line of surgical and non-surgical products for the spine, orthopedics, sports medicine and vascular market sectors. The Company operates in four segments: Domestic, Spinal Implants and Biologics, Breg, and International. Domestic consists of operations of its subsidiary Orthofix Inc. Spinal Implants and Biologics consists ofBlackstone Medical, Inc., and its two subsidiaries, Blackstone GmbH and Goldstone GmbH. Breg designs, manufactures, and distributes orthopedic products for post-operative reconstruction and rehabilitative patient use and sells those Sports Medicine products through a network of domestic and international distributors, sales representatives, and affiliates. International consists of locations in Europe, Mexico, Brazil, and Puerto Rico, as well as independent distributors outside the United States.
Shares of Orthofix International (NASDAQ: OFIX) traded up 2.35% during mid-day trading on Tuesday, hitting $27.93. Orthofix International has a 52 week low of $26.00 and a 52 week high of $38.60. The stock’s 50-day moving average is $27.5 and its 200-day moving average is $29.58. On average, analysts predict that Orthofix International will post $0.57 EPS next quarter. The company has a market cap of $495.1 million and a price-to-earnings ratio of 10.56.